Download presentation
Presentation is loading. Please wait.
1
Neonatal Group B Streptococcal Infections
Perinatal CDC Prevention Guidelines Priscilla Joe, MD
2
The Disease Leading cause of early-onset sepsis in US
Prior to intrapartum prophylaxis: 8,000 cases/year or 2/1000 live births Reduced now to 1,600 cases/year or 0.6/1000 live births Perinatal GBS disease burden Neonatal illness/death, long-term disability Maternal morbidity
3
Mother to Infant Transmission
GBS colonized mother 50% 50% Non-colonized newborn Colonized newborn 98% 2% MATERNAL-TO-INFANT TRANSMISSION Most group B streptococcal disease cases among newborns result from mother-to-infant transmission during labor and delivery. Many women are asymptomatically colonized by group B streptococcus in the genital and gastrointestinal tracts. Colonization is not altered by or dependent on pregnancy. About half the infants born to colonized mothers are themselves colonized on the skin and mucosal surfaces as a result of passage through the birth canal or as a result of GBS ascending into the amniotic fluid. The majority of colonized infants, 98%, are asymptomatic. About 2% will develop early-onset disease, presenting with sepsis, pneumonia or meningitis in the first few days of life. Early-onset sepsis, pneumonia, meningitis Asymptomatic
4
Colonization Rates GBS Carriers
10% - 30% of women Higher in African Americans and nonsmokers Clinical signs not predictive Dynamic condition Risk factor for early-onset disease: GBS colonization at delivery Prenatal cultures late in pregnancy predict delivery status
5
Additional Risk Factors for Early-Onset GBS Disease
Obstetric: prolonged rupture of membranes, preterm delivery, intrapartum fever GBS bacteriuria Previous infant with GBS disease Demographic (African American, young age) Immunologic (low antibody to GBS capsular polysaccharide)
6
Prevention of Perinatal GBS Disease
Intrapartum antibiotics Highly effective at preventing early-onset disease in women at risk for transmission of GBS to their newborns Challenge: How best to identify women at risk?
7
Rates of Early-Onset GBS Disease by Prenatal Colonization & Risk Factors
Col: prenatal vag/rect culture RF: risk factors (gest. <37 wks, ROM >18 hr, fever > 37.5°C) RATES OF EARLY-ONSET GBS DISEASE BY PRENATAL COLONIZATION & RISK FACTORS A main consideration in development of prevention guidelines was characterizing which women were at risk for delivering infants with early-onset infection This slide summarizes data from a prospective study conducted in the early 1980s by Boyer and Gotoff (published in Antibiotics and Chemotherapy in 1985) that assessed nearly 5300 infants born over a three-and-a-half year period, none of whom had received intrapartum antibiotics. The cohort of deliveries was considered in terms of maternal prenatal colonization with group B streptococcus and the presence of an intrapartum risk factor, either pematurity, prolonged rupture of membranes, or intrapartum fever. The attack rate was quite high among infants born to colonized mothers with one or more risk factors, 40.8 per 1000 births, or about 1 in 25 infants. Infants born to colonized mothers without a risk factor had the next highest risk of early onset infants with an attack rate of 5.1 per 1000 births. Infants born to mothers with risk factors who were not prenatally colonized and to mothers who were neither colonized nor had risk factors, had very low attack rates of 0.9 per 1000 births and 0.3 per 1000 births, respectively. Boyer & Gotoff, Antibiot Chemother 1985.
8
First U.S. Consensus Recommendations (CDC '96, ACOG '96, AAP '97)
Screening-based approach: 35-37 wks culture, offer intrapartum antibiotic prophylaxis (IAP) to GBS carriers and to preterm unless neg. culture result available, or Risk-based approach: IAP to preterm, membrane rupture>18 hours, or intrapartum fever (T>38°C) Both strategies also give IAP to women with GBS bacteriuria, or previous infant with GBS disease FIRST U.S. CONSENSUS RECOMMENDATIONS (CDC ’96, ACOG ’96, AAP ’97) In 1996 guidelines were issued by the Centers for Disease Control and Prevention, American College of Obstetricians and Gynecologists, and American Academy of Pediatrics. These guidelines recommend health care providers and institutions choose between two alternative prevention strategies: Screening-based approach Pregnant women should be cultured between weeks Intrapartum antibiotic prophylaxis (IAP) should be offered to women identified as GBS carriers and to women of unknown GBS status at the time of labor who are delivering preterm Risk-based approach IAP to preterm, membrane rupture from 18 hrs or more, or for an intrapartum fever of 100.4F or more (38C or more) Both strategies also give IAP to women with GBS bacteriuria or previous infant with GBS disease
9
Why is screening more protective than the risk-based approach?
Broader coverage of at-risk population Captures colonized women without obstetric risk factors (18% of all deliveries) Antibiotic effectiveness in this cohort, based on birth survey data: 89% (64-97%) Schrag et al, NEJM 2002, 347:233-9
10
Intrapartum Prophylaxis: Indications
Previous infant with invasive GBS disease GBS bacteriuria during current pregnancy Positive GBS screening culture during current pregnancy (unless a planned c-section, in the absence of labor or amniotic membrane rupture) Unknown GBS status AND any of the following: Delivery at < 37 weeks’ gestation Amniotic membrane rupture >18 hours Intrapartum temperature >38.0°C
11
Intrapartum Prophylaxis NOT Indicated
Prior pregnancy with a positive GBS screening culture (unless culture positive ALSO during current pregnancy) Planned c-section performed in the absence of labor or membrane rupture (regardless of maternal GBS culture status) Negative vaginal and rectal GBS screening culture during the current pregnancy, regardless of intrapartum risk factors
12
Maternal Antibiotic Prophylaxis
Dose given Neonatal colonization < 1 hr 46% similar to no treatment 2 to 4 hrs 2.9% > 4 hrs 1.2%
13
Neonatal Management Algorithm
14
Neonatal Management Algorithm
15
Early Onset Disease Presentation within 1st 24 hrs, 0 - 6days
75% of cases of GBS disease Vertical transmission Sepsis 25-40% Pneumonia 35-55% Meningitis 5-10% Mortality 5%; higher in preterm infants Due to opsonin deficiency, limited maternal antibody transfer, limited maternal capsular antibody
16
Late Onset Disease 3-4 weeks after birth, range 7d-3mo
Term and preterm infants equally susceptible Serotype III most common and predominant cause of meningitis Bacteremia and meningitis Osteomyelitis, septic arthritis, and cellulitis Horizontal transmission (hospital, community, mother) Incidence unchanged with intrapartum prophylaxis
17
Treatment of Asymptomatic Neonates
24-48 hr observation period for infants with pretreated mothers Routine use of antibiotics in infants whose mothers received adequate treatment is not indicated
18
Diagnosis Blood, CSF, ETT cxs CBC CRP CXR
19
Treatment of GBS Disease
Ampicillin and Gentamicin 7-10 days for uncomplicated bacteremia 14 days for uncomplicated meningitis 21-28 days for meningitis complicated by abscesses, ventriculitis 4-6 weeks for osteomyelitis or endocarditis
20
References
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.